Click it and Unblock the Notifications
JN.1 Subvariant of Omicron Detected in Kerala
In a concerning development, the health ministry reported 335 new Covid-19 cases in India on Sunday, contributing to an increase in active cases, which now stand at 1,701. Additionally, the nation mourns five new deaths, with four fatalities recorded in Kerala and one in Uttar Pradesh. The total Covid caseload in the country has reached a staggering 45 million.
Unveiling JN.1: A Subvariant with Unique Traits
Adding to the challenges, a new subvariant of the Omicron variant, named JN.1, has surfaced in Kerala, India. Originating from the Omicron subvariant BA.2.86 or Pirola, which has been circulating globally, JN.1 exhibits a mutation in the spike protein, specifically L455S. While this mutation may aid in evading the immune system, there is no conclusive evidence suggesting increased severity or transmissibility compared to other variants.
JN.1: Symptoms and Observations
Reports indicate that JN.1 shares common symptoms with other Covid-19 variants, including fever, cough, tiredness, nasal congestion, runny nose, diarrhea, and headaches. Notably, some unconfirmed reports suggest a potential increase in gastrointestinal symptoms, such as abdominal pain and diarrhea, setting it apart from its predecessors.
Geographical Spread and Evolution of JN.1
First detected in the Kerala district of Karakulam, Thiruvananthapuram, on December 8, 2023, JN.1 has emerged as a descendant of Pirola. Its presence in India follows previous detections in the United States and China. The new variant carries a single mutation in the spike protein compared to the earlier strain Pirola or BA.2.86 found in Karakulam, Thiruvananthapuram. Despite similarities with previous Omicron strains, vigilance is crucial, particularly for vulnerable populations.
CDCP Warning and Global Concerns
The Center for Disease Control and Prevention (CDCP) in the United States issued a warning after seven cases of JN.1 were identified in China on December 15. The CDCP expressed concerns about a potential impact on the healthcare system due to a rise in Covid-19 cases. Tracking by the CDCP indicates a significant increase in the share of cases attributed to the new variant.
Infectivity and Transmissibility of JN.1
JN.1 constitutes 15-29% of cases in the United States, displaying increased infectivity and transmissibility. Notably, hospitalizations have not seen a corresponding surge, and symptoms remain relatively mild. Gastrointestinal symptoms, particularly abdominal pain and diarrhea, show a higher incidence with JN.1, although further studies are required to confirm these observations.
Protective Measures: Vaccination and Protocols
To shield against JN.1 and other Covid-19 variants, health experts emphasize getting vaccinated with the updated Covid-19 vaccine designed to target XBB variants, including JN.1. Despite the availability of updated vaccines since mid-September, only 7.1% of adults and 2.1% of children eligible for the updated doses have received them. Vaccination remains the most effective defense against severe illness and hospitalization.
Preventive Measures: A Call for Collective Action
In addition to vaccination, adherence to Covid-19 protocols is crucial. Wearing masks, maintaining physical distance, avoiding crowded and poorly ventilated spaces, frequent handwashing, and staying home when unwell contribute to reducing the risk of exposure and transmission. Vigilance over symptoms and seeking prompt medical attention for any signs of Covid-19 are essential steps in controlling the potential spread of JN.1 and other variants.
